What is Biolinq?
Biolinq is a healthcare technology company dedicated to improving metabolic health through advanced, non-invasive biosensing solutions. The company's core technology involves microsensors that reside just below the skin's surface, providing users with real-time, actionable data regarding their metabolic status. By focusing on simplicity and precision, Biolinq aims to empower individuals to manage their health proactively, effectively bridging the gap between clinical-grade diagnostics and consumer-friendly wearable devices. Its market position is defined by its commitment to addressing the global burden of metabolic diseases through scalable, high-impact medical technology.
How much funding has Biolinq raised?
Biolinq has raised a total of $273.1M across 5 funding rounds:
Series A
$14.8M
Debt
$350K
Series B
$100M
Other Financing Round
$58M
Series C
$100M
Series A (2019): $14.8M with participation from Aphelion Capital, LifeSci Venture Partners, Hikma Pharmaceuticals, M Ventures, Three Leaf Ventures, and JDRF T1D Fund
Debt (2020): $350K led by PPP
Series B (2021): $100M supported by RiverVest Venture Partners
Other Financing Round (2024): $58M featuring Pegasus Tech Ventures and Alpha Wave Global
Series C (2025): $100M backed by Aphelion Capital, Alpha Wave Global, Hikma Ventures, Taisho Pharmaceutical Holdings, AXA, RiverVest Venture Partners, LifeSci Venture Partners, and M5 Venture
Key Investors in Biolinq
RiverVest Venture Partners
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs. The firm aims to enhance patient lives, support entrepreneurs, and gain the trust of investors through its commitment to science, strategy, and innovation.
Aphelion Capital
Aphelion Capital invests in medical technology companies across all stages and therapeutic areas, with a strong preference for investments that improve quality of care while reducing costs in the healthcare system.
M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, investing globally in transformational ideas driven by great entrepreneurs to translate innovation towards commercial success.
What's next for Biolinq?
With the successful closure of this major strategic investment, Biolinq is entering a critical phase of operational scaling and product deployment. The company is expected to utilize these funds to expand its manufacturing capabilities, advance its clinical validation programs, and refine its data analytics platform to enhance user engagement. As the demand for continuous glucose and metabolic monitoring grows, Biolinq is well-positioned to capture significant market share by providing a seamless, user-centric experience that simplifies complex health data. Future strategic initiatives will likely focus on regulatory milestones and the integration of its biosensor technology into broader digital health ecosystems, further solidifying its role as a transformative force in the life sciences sector.
See full Biolinq company page
